multiple sclerosis

(redirected from relapsing-remitting multiple sclerosis)
Also found in: Dictionary, Medical, Encyclopedia.
  • noun

Synonyms for multiple sclerosis

a chronic progressive nervous disorder involving loss of myelin sheath around certain nerve fibers

References in periodicals archive ?
We are continuing to add to the body of evidence supporting interferon beta-1b, and we remain steadfastly committed to uncovering new insights into relapsing-remitting multiple sclerosis," said Dario Mirski, M.
Prof Carole Longson, director of the health technology evaluation centre at Nice, said: "The latest draft guidance from our committee recommends the NHS use of fingolimod for a specific group of adults who have highly active relapsing-remitting multiple sclerosis.
Between November, 2003, and June, 2005, 2447 patients with relapsing-remitting multiple sclerosis were screened and 2244 patients were enrolled in this prospective, multicenter, randomized trial.
The 33-year-old Sutton is the first person with relapsing-remitting multiple sclerosis (RRMS) known to race in any NASCAR Series.
All had clinically definite relapsing-remitting multiple sclerosis and no previous treatment with interferons or glatiramer in the previous 3 months or corticosteroids within 30 days of screening (Lancet 363[9421]:1607-08, 2004).
A comparison of the biologic activity of two recombinant IFN-beta preparations used in the treatment of relapsing-remitting multiple sclerosis.
An immune-suppressing agent for reducing neurologic disability and/ or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis.
Betaseron decreases the frequency and severity of acute attacks in people with relapsing-remitting multiple sclerosis, but at the moment, we don't know why.
In addition, the Company has an oral therapy for relapsing-remitting multiple sclerosis in clinical development.
Food and Drug Administration (FDA) approved BETACONNECT, the first and only electronic autoinjector in the treatment of relapsing-remitting multiple sclerosis (RRMS).
The Scottish Medicines Consortium (SMC) today published its advice that Lemtradahas been accepted for use within NHS Scotland for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS), with active disease defined by clinical or imaging features.
Rebif in the clinical trials, which was sustained despite infrequent administration, represents an approach to treatment that promises to reshape the future for many people with active relapsing-remitting multiple sclerosis.
It said it was unclear how much the drug would help the specific group of people for whom it was licensed - adults with relapsing-remitting multiple sclerosis (RRMS) who experienced at least one relapse a year despite being treated with beta interferon drugs.
The trial recruited 21 patients between 20 to 53 years of age, who had relapsing-remitting multiple sclerosis that had not responded to at least six months of treatment with interferon beta.
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis.